## Xiao Ni

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11774294/publications.pdf

Version: 2024-02-01

	840119		1058022	
15	610	11	14	
papers	citations	h-index	g-index	
15	15	15	761	
all docs	docs citations	times ranked	citing authors	

#	Article	IF	CITATIONS
1	Minimal Clinically Important Differences in the Erectile Function Domain of the International Index of Erectile Function Scale. European Urology, 2011, 60, 1010-1016.	0.9	324
2	Testosterone Replacement in Androgen-Deficient Men With Ejaculatory Dysfunction: A Randomized Controlled Trial. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 2956-2962.	1.8	63
3	Automatic model selection for partially linear models. Journal of Multivariate Analysis, 2009, 100, 2100-2111.	0.5	42
4	Direct Effects of Tadalafil on Lower Urinary Tract Symptoms versus Indirect Effects Mediated through Erectile Dysfunction Symptom Improvement: Integrated Data Analyses from 4 Placebo Controlled Clinical Studies. Journal of Urology, 2014, 191, 405-411.	0.2	32
5	Clinical and Demographic Correlates of Ejaculatory Dysfunctions Other Than Premature Ejaculation: A Prospective, Observational Study. Journal of Sexual Medicine, 2015, 12, 2276-2286.	0.3	26
6	Delayed Ejaculation and Associated Complaints: Relationship to Ejaculation Times and Serum Testosterone Levels. Journal of Sexual Medicine, 2017, 14, 1116-1124.	0.3	24
7	Efficacy of Continuous Dosing of Tadalafil Once Daily vs Tadalafil On Demand in Clinical Subgroups of Men with Erectile Dysfunction: A Descriptive Comparison Using the Integrated Tadalafil Databases. Journal of Sexual Medicine, 2016, 13, 860-875.	0.3	20
8	The Co-occurring Syndrome—Coexisting Erectile Dysfunction and Benign Prostatic Hyperplasia and Their Clinical Correlates in Aging Men: Results From the National Health and Nutrition Examination Survey. Urology, 2015, 86, 570-580.	0.5	18
9	9-Month Efficacy and Safety Study of Testosterone Solution 2% for Sex Drive and Energy in Hypogonadal Men. Journal of Urology, 2016, 196, 1509-1515.	0.2	15
10	Minimal Clinically Important Differences in the Vaginal Insertion and Successful Intercourse Items of the Sexual Encounter Profile. Journal of Sexual Medicine, 2012, 9, 169-179.	0.3	14
11	Erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia ( <scp>LUTS</scp> / <scp>BPH</scp> ) combined responders to tadalafil after 12 weeks of treatment. BJU International, 2016, 118, 153-160.	1.3	12
12	Nonresponders, Partial Responders, and Complete Responders to PDE5 Inhibitors Therapy According to IIEF Criteria: Validation of an Anchor-Based Treatment Responder Classification. Journal of Sexual Medicine, 2013, 10, 3029-3037.	0.3	8
13	The Role of Initial Success Rates and Other Factors in Determining Reliability of Outcomes of Phosphodiesterase Inhibitor Therapy for Erectile Dysfunction: A Pooled Analysis of 17 Placebo-Controlled Trials of Tadalafil for Use as Needed. Journal of Sexual Medicine, 2013, 10, 541-550.	0.3	6
14	Efficacy and Safety of Once-Daily Tadalafil in Men with Erectile Dysfunction Who Reported No Successful Intercourse Attempts at Baseline. Journal of Sexual Medicine, 2013, 10, 844-856.	0.3	6
15	Reply. Urology, 2015, 86, 580.	0.5	O